

**IN THE SPECIFICATION:**

The Application contains a Sequence Listing containing Sequence ID Nos: 1-11. The Sequence Listing is incorporated herein in its entirety for all purposes.

**IN THE CLAIMS:**

The application contains an Article 34 amendment amending claims 1 through 3 and 5 and adding new claims 6 and 7. The Article 34 amendment is incorporated herein in its entirety for all purposes.

**LISTING OF THE CLAIMS**

1. (Previously Presented) A cancer treatment drug comprising a transcriptional factor as an effective component, which comprises p53 or a mutated type p53, wherein one or more amino acids are deleted, substituted or added with respect to the amino sequence of p53, and clathrin heavy chains.
2. (Previously Presented) The cancer treatment drug of claim 1, wherein at least the serine residue at amino acid position 46 is substituted in said mutated type p53.
3. (Previously Presented) The cancer treatment drug of claim 2, wherein said serine residue at amino acid position 46 is substituted to phenylalanine.
4. (Canceled)
5. (Previously Presented) A method for treating cancer comprising injecting a transcriptional factor, which comprises p53 or a mutated type p53, wherein one or more amino acids are deleted, substituted or added with respect to the amino sequence of p53, and clathrin heavy chains to a cancer cell, or injecting clathrin heavy chains to a cancer cell.

6. (Previously Presented) The method for treating cancer of claim 5, wherein at least the serine residue at amino acid position 46 is substituted in said mutated type p53.

7. (Previously Presented) The method for treating cancer of claim 6, wherein said serine residue at amino acid position 46 is substituted to phenylalanine.